Right, NWBO was exempted from needing the pediatric trials initiated prior to maa submission, but they’ll need them initiated by approval. Imho.
Note: I’m more excited than I once was about this, because I’m hopeful the pediatric trials will include poly-iclc, which appears to increase the therapeutic indication range for DCVax-l. Something desperately needed in childhood brain cancer.
Market Data 
Markets 
AI
